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A New Class of Monoamine Oxidase Inhibitors 
R. R. Vunnam, D. Bond, R. A. Schatz, N. S.  Radin, and N. NarasimhacharP 
Abstract: Newly synthesized compounds have been found to  inhibit mito- 
chondrial monoamine oxidase (MAO) in mouse brain and rat liver. A series of 
2-acylamino-3-trrt-aminopropiophenones acted preferentially against M A 0  
type  B (2-phenylethylamine a s  substrate) ,  apparent ly  irreversibly. 2- 
Decanoylamino-3-morpholinopropiophenone acted similarly irr  live toward the 
cerebral MAO, producing a dose-related inhibition. At high dose levels, M A 0  
type A was also severely inhibited. The effects were produced rapidly and 
restoration of enzyme activity also appeared rapidly. The half-life for M A 0  
type A could be estimated from the rate of enzyme reappearance to be 13 h. It 
is suggested that the amino ketones undergo a /3-elimination reaction at the 
enzyme's active site, forming a reactive species (an a$-unsaturated ketone), 
which reacts covalently with a nucleophilic group of the enzyme by a Michael 
addition. Some other related compounds, derivatives of phenylpropane, also 
showed inhibitory activity against MAO, particularly against type A (serotonin 
as  substrate). The morpholino compound might have promise as a quickly 
effective, short-acting inhibitor of M A 0  type B. Key words: Monoamine 
oxidase inhibitors-Monoamine oxidase type B-2-Decanoylamino - 3 - 
morpholinopropiophenone-Monoamine oxidase half-life. 
In the course of an attempt to develop inhibitors 
of g lucocerebros ide  syn the ta se ,  ana logs  of 
ceramide were synthesized and evaluated with an in 
t i f r o  assay. When some of the compounds were in- 
jected into mice, symptoms such as head twitches, 
tremor, and abduction of the hind legs were pro- 
duced, indicating that these compounds have CNS 
effects. Subsequent tests for effects on monoamine 
oxidase [EC 1.4.3.4, amine:oxygen oxidoreductase 
(deaminating) (flavine containing)] showed that they 
exhibited appreciable inhibitory activity. Since 
some of the compounds constituted a new class of 
inhibitors of this enzyme, we made a more detailed 
study of their effects on monoamine oxidase (MAO) 
in rodent liver and brain, with special emphasis on 
the question of differential sensitivity toward the 
two types of enzyme, A and B (Johnston, 1968; Neff 
et al., 1974). It is currently of considerable interest 
to determine whether selective inhibition of the two 
types would be clinically useful in the treatment of 
human disorders, neurological, behavioral, or cir- 
culatory. 
MATERIALS AND METHODS 
2-(N-acylamino)-3-substituted aminopropiophenones 
were prepared from 2-amino-acetophenone (Wolfheim, 
1914) by acylation, followed by a Mannich reaction with 
paraformaldehyde and a secondary amine in the presence 
of HCI. For  example, the acetyl compound (RV-433) was 
m a d e  b y  d i s s o l v i n g  2 . 2  g ( 1 2 . 5  m m o l )  o f  2 -  
acetaminoacetophenone (Wolfheim, 1914), 0.5 g (5.5 
mmol) of paraformaldehyde, and 1.5 ml( l7 .2  mmol) mor- 
pholine in 15 ml ethanol and adding 0.3 ml of concentrated 
HCI. The mixture was refluxed for 15 h;  then, about 10 ml 
of the solvent were removed with a rotary vacuum 
evaporator. The mixture was diluted with 30 ml of water 
and adjusted with HCl to  pH 3 ,  and nonbasic impurities 
were removed by extracting with 45 ml of ether. The re- 
maining material was made alkaline with ammonium hy- 
droxide and the free base was extracted into 2 x 30 rnl of 
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ethyl acetate. The pooled extracts were washed with 
saline and dried with Na,SO,, and the solvent was re- 
moved. The amine was converted to a crystalline salt by 
dissolving it in 10 ml of EtOAc and adding 2.3 g (12 mmol) 
ofp-toluenesulfonic acid hydrate in EtOAc. The resultant 
precipitate was crystallized twice from methanol. The 
yield was 72% (4 g), m.p. 191-2°C. 
Analysis: C,,H,,,N,O,,.C,H,O,,S (mol. wt. 448.5). Cal- 
culated, 58.92% C (found 58.83), 6.29% H (6.18), 6.25% N 
(6.24). 2-Decanoylamino-3-morpholinopropiophenone 
(RV-378) was prepared similarly from 2-decanoylamino- 
acetophenone (m.p. 79-80"C, from benzene-hexane) but 
isolated as the hydrochloride (yield 62%, m.p. 137-8°C 
from EtOAc). 
Analysis: C,,,H,,,,N,O,,.HCI (mol. wt. 425.0). Calcu- 
lated, 65.00%' C (found 65.13), 8.78% H (8.82), 6.59% N 
(6.52). 
The piperidine analogue of RV-378 (RV-471) was also 
prepared: 2 - decanoylamino - 3 - piperidinopropiophenone 
toluenesulfonic acid salt (yield, 30%, m.p. 87-9°C from 
EtOAc). On drying over P,O, in vacuum at 23°C it be- 
came hygroscopic and gave an analysis indicating the 
presence of one molecule of water. 
Analysis: C,,,H,,,N,O,,S.H,O (mol. wt. 576.8). Calcu- 
lated: 64.56% C (found 64.97), 8.39% H (8.64), 4.86% N 
(4.97). 
2-Decanoylamino-3-morpholino- 1-phenyl- 1 -propano1 
was made from 1.7 g (4 mmol) of RV-378 in 25 ml 
methanol. To this was added 1 . 1  g of K,CO,, in 2 ml water, 
followed by 0.8 g of NaBH, in small portions over a 30- 
min period. After 3 h of stirring, most of the solvent was 
removed in i ~ ~ i c i w  and the residue was shaken with 10 ml 
of water and 75 ml of EtOAc. The organic phase was 
washed with 10% salt, dried over Na,SO,, and the solvent 
removed. The amine was converted t o  the hydrochloride 
with HCI in isopropanol, evaporated to  dryness, and 
triturated with ether. The product (RV-538b) melted at  
107 - 113°C after crystallization from chloroform-ether; 
yield, 1.5 g. Silica gel T L C  with chloroform-methanol, 
95:5 (v/v), revealed two spots very close to each other, 
indicating that the reduction yielded the threo- and 
erythro-isomers. For elemental analysis, the salt was re- 
crystallized from EtOAc, converted to  the free base with 
NaHCO,,, and purified with a silica gel column, using 
chloroforrn/methanol/ammonium hydroxide (concd.)  
96:4:0.5 and 94:6:0.5 (by vol.). The melting point was 
96-7°C (from hexane). This material (RV-538a) showed 
only the faster-moving spot with TLC. 
Analysis: C,:,H,,,N,O,, (mol. wt. 390.6). Calculated, 
The infrared spectra of the compounds were obtained 
with the KBr pellet technique. The expected two carbo- 
nyl bands were seen in the case of the keto amides, at 
about 5.94 and 6.05 pm. The reduced ketone (RV-538) 
showed only the amide C=O band at 6.05 pm. 
The preparation of other compounds tested in this 
study has been reported (Hyun et al., 1975) or will be 
reported separately. 
Adult mice (Swiss-Webster, 25-30 g) from Charles 
River Laboratories were used. For whole homogenate 
studies, brains were homogenized in 5- 10 volumes of 50 
mM-potassium phosphate, p H  7.4. Mitochondria were 
prepared by homogenizing brain in 4 vol. of 0.32 M- 
sucrose, centrifuging at 700 g for 15 min, washing the 
pellet, and centrifuging the combined washings at 20,000 
70.73%. C (found 70.76), 9.81% H (9.74), 7.17% N (7.13). 
g for 30 min. The mitochondria1 pellet was washed with 
sucrose and suspended in buffer as  above. Monoamine 
oxidase was determined in the brain preparations with 0.1 
~ M - ~ - H T  (serotonin) or PEA (phenethylamine) as sub- 
strates (Owen et al., 1977). 
Rat  l iver  mitochondria  were  prepared  similarly 
(Hogeboom, 1955) and tested with 35 pM-[l'C]tyramine as  
substrate, in 0.2 M-phosphate, pH 7.4. 
The inhibitors were tested by evaporating a solution to 
dryness in each test tube or  adding freshly prepared 
aqueous solutions. Protein was determined with modified 
Folin reagent (Lowry et al., 1951). 
RESULTS 
A survey of various related compounds in tests 
with brain M A 0  (Table 1) showed that some com- 
pounds were preferentially active against M A 0  
type A (RV-83 and 125) and some were preferen- 
tially active against M A 0  type B (RV-378, 470,471, 
472). A compound not shown in the table, RV-252 
(N- [n- decyl] -N ' -p  -methox yphenyl guanidine), was 
rather active at 0.2 mM against both types of MAO: 
55% inhibition against 5-HT oxidation and 36% 
against PEA oxidation. The corresponding values 
obtained without preincubating the inhibitor were 
not much different: 61% and 28%. With some com- 
pounds, particularly the ketones, adding the sub- 
strate at  the same time as the inhibitor reduced 
the inhibitory effect. The importance of the carbonyl 
group adjacent to the phenyl ring was shown by 
the drastically decreased inhibitory activity of the 
reduced compound (RV-378 versus 538). 
Compounds RV-472 and 470 proved difficult to 
purify and were not studied in detail. They were not 
as selective as the other keto amines with respect to 
inhibition of the different types of MAO. Tol- 
uenesulfonic acid, used to prepare some of the 
amines in crystalline form, was not itself inhibitory 
to MAO. 
The degree of inhibition by the keto amines on 
M A 0  type B resulting from preincubation with 
brain mitochondria was found to increase with du- 
ration of exposure to the inhibitor (Fig. 1) .  This in- 
dicates that the inhibitors acted by causing inacti- 
vation of the enzyme. The disappearance of enzyme 
activity was rapid at first, then slowed somewhat. 
Note the lack of a lag period, indicating that the 
inhibition was due to the added compound, not to a 
metabolically produced derivative of the inhibitor. 
Evidence for the irreversibility of the inhibitory 
action of the keto amines was obtained (Table 2) by 
dialyzing the mitochondria after preincubating them 
with the inhibitors. Dialysis prior to incubating the 
preparation with substrate, which should have led 
to the removal of the inhibitor, did not restore the 
activity of the enzyme. 
Tyramine is considered a nonselective substrate 
for types A and B M A 0  (Neff et al., 1974). When 
this substrate was used with rat liver mitochondria, 
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TABLE 1 . I t i  / I  ibitiou o f  ni oiisc hru iri  in o t i o u  miti  e oxiduses by 2-drccrnoylu m ino- 
3 - 1 ~ 0 r p  holiriopropiop h etio I 14 uiid re luted conipoit tids 
R O X -  fH-R" 
R' 
Compound Percent  i n h i b i t i o n  
number Sero tonin  Phenethylamine 
X R R' R" 





RV-4 71 I 1  I1 11 -CH2N 3 8 (8) 7 1  (9) 
19 (22) 63 (33) 
RV-470 I1 11 11 -CH2N(Me)C H OH 30 (15) 58 (46) 
-CH N 11 11 I 1  RV-472 
9 -  9 (11) 
I 1  11 -CH N n2 RV-538b CHOH 
RV-128 -CONHNH2 35 (0) - (3) 11 11 11 
RV-83 CHNHCloH21 11 OH -CH20H 4 1  (56) 28 (23) 
- - 1 2  - I 1  -NHC10H21 RV-218 CHOH NO2 
I 1  I 1  31 (27) 20 (27) NH2 
II RV-125 
-CH2NH2 7 (0) 31 (38) I1  H II RV-143 
All compounds were tested at 0.1 mM except the last five (0.2 mM) with mitochondria and substrates at 0.1 mM. The values shown are 
for the degree of inhibition obtained when the inhibitors were incubated for 30 min with the mitochondria before addition of substrate 
and incubation for 30 min more. The values in parentheses were obtained when the inhibitor was added together with the substrate. 
Compounds 378, 470, and 538 were hydrochlorides, 471, 218, and 143 were toluenesulfonates, 472 was a citrate, and 83 was the hydro- 
bromide. The control M A 0  activity (in nmoYmg proteinih) was 27.4 for 5-HT and 22.4 for PEA. 
the keto amines were found to be much more effec- 
tive inhibitors than they were in mouse brain tested 
with PEA or 5-HT (Table 3). All the keto amines 
showed rather similar inhibitory power, except for 
RV-433, a homologue of the decanoylamino mor- 
pholine derivative in which the acyl group was 
acetyl instead of decanoyl. Evidently, a lipoidal side 
chain in the amide position produces more effective 
inhibition. By way of comparison, we found 50% 
inhibition of tyramine deamination with 0.1 PM- 
phenelzine, a clinically useful M A 0  inhibitor. 
Intraperitoneal injection of mice with isotonic 
saline (10 ml/kg) or with RV-378 in saline, followed 
by sacrifice 2 h later, showed that the compound 
inhibited cerebral M A 0  in vivo (Fig. 2 ) .  At the low- 
est dosage level tested (25 mg/kg), type B M A 0  in 
brain was inhibited to a greater extent than was type 
A (35% versus 12%). As the dosage was increased, 
this difference decreased. 
A similar in vivo study with a dose level of 250 
mglkg of RV-378 showed that the two types of M A 0  
in brain were largely inactivated within 1 h (Fig. 3). 
Resynthesis (or reactivation) of M A 0  type A (the 
upper curve) became noticeable promptly after the 
minimum was reached, and the level of enzyme was 
almost back to normal within 24 h. The rate of syn- 
thesis or reactivation of M A 0  type B (lower curve) 
was apparently slower. The reappearance of func- 
tional M A 0  molecules soon after the first hour fol- 
lowing injection indicates that the inhibitor was 
rapidly destroyed, sequestered, or excreted. 
Additional evidence for the rapid loss of inhibitor 
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FIG. 1. Effect of preincubating mouse brain MA0 for differ- 
ent lengths of time with RV-378 (A) and RV-471 (6) .  The in- 
hibitors were preincubated with mitochondria for the indi- 
cated times at the indicated concentrations; then the prepa- 
rations were tested for MA0 activity with 0.1 mM PEA. The 
control MA0 activity was 21.5 nmolimg proteinih. 
was obtained by assaying mixtures of brain homog- 
enate from control and from drug-treated mice 
(Table 4). The brain homogenates from mice sac- 
rificed 1 or 2 h after injecting RV-378 were mixed 
with an equal amount of the control brain homoge- 
nates and then assayed for M A 0  activity with PEA 
and 5-HT. The expected (mean) value was obtained 
with PEA, indicating that no free inhibitor remained 
in the drug-treated animals. In the case of 5-HT 
assays, the specific activity of the mixed tissues was 
even higher than expected. 
TABLE 2. Acriviiy of monoatnine o.uidase ( type B )  in 
diulyicd and undialyzed mouse brain mitochotidria 
prcireatecl with inhibitor 
~~~ 
Dialyzed enzyme Undialyzed enzyme 
Inhibitor (nmoVNmg protein) (nmoUNmg protein) 
None 25.1 21.7 
RV-378 6.4 (75) 7.8 (64) 
RV-471 7.2 (71) 7.8 (64) 
Mitochondria were incubated for 30 min with inhibitor at 
0.1 mM, then assayed directly or dialyzed overnight against 
two changes of 5 mwpotassium phosphate, pH 7.4. M A 0  type 
B was assayed with 0.1 mM-PEA as substrate. The numbers in 
parentheses indicate the degree of inhibition (percent) compared 
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Rat liver mitochondria were preincubated with varying con- 
centrations of inhibitor and then assayed with 35 pM-tyramine: 
the IC,,, level was determined from the graphed data. 
" This is the acetyl homolog of RV-378; '' the reduced version 
of RV-378. 
DISCUSSION 
4-Morpholinobutyrophenone (NSD 2023) is 
known to be a M A 0  inhibitor (Squires and Lassen, 
1968; Christmas et al., 1972). The latter study 
showed that the drug produced preferential inacti- 
vation of the type A enzyme in brain (5-HT and 
benzylamine as substrates) after oral administration 
to rats. Our most active compounds showed prefer- 
ential action on the type B enzyme, which may be 
due to their having one less carbon atom in the ali- 
phatic side chain and a long hydrophobic acylamino 
group between the ketonic and basic groups. 











FIG. 2. Effect of varying doses of RV-378 on mouse brain 
MA0 activity. Mice were injected intraperitoneally with saline 
(10 mlikg) or the indicated dose of inhibitor and killed 2 h 
later. Enzyme activity was determined in mouse brain ho- 
mogenates using 0.1 mM-PEA or 5-HT. Each point represents 
the mean activity (nmolimg proteinih) e S.E.M. of five mice. 
The open symbols denote a significant difference compared 
with saline-treated mice at the 0,001 level (Student's t-test). 
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T h e  ke tone  group might ac t  additionally by 
facilitating binding of the inhibitor to the active site 
by formation of a Schiff base with an amino group. 
The idea that the keto amines react covalently 
with the enzyme is also supported by the finding 
that preincubation, before substrate addition, pro- 
duces greater inhibition of the enzyme (Table 1). 
Evidently, the inhibitor and PEA competed for en- 
trance into the active site that has the type-B spec- 
ificity. In the case of the type-A reactive site, 5-HT 
seemed to compete effectively when the inhibitor 
was at a low concentration. 
The failure of the keto amine to inactivate all of 
:b;
inhibition in vitro was relatively large for our com- 
pounds compared with available M A 0  inhibitors, 
they were not remarkably less effective in vivo. For 
example, pargyline is generally used at the 50 or 100 
mg/kg dosage with rats and iproniazid at the 100 
mg/kg level. We obtained strong effects with about 
50 mg/kg (Fig. 2). 
Comparison of the activities of the morpholino 
ketone (RV-378) with the morpholino alcohol (RV- 
538) supports the idea that the carbonyl group 
facilitates conversion of RV-378 t o  a reactive 
species that is responsible for the M A 0  inhibition. 
Aromatic p-keto amines are known to undergo 
spontaneous  breakdown in aqueous  solution 
(Schonenberger et al., 1969), forming the secondary 
amine and the substituted acrylophenone. The latter 
reactive product, the formation of which might be 
facilitated by the active site of MAO, would be ex- 
pected to react with nearby nucleophilic groups in 
the enzyme (Andrisano et al., 1967): 
(A similar curve is seen in a semilog plot of the data; 
if a single reaction were involved, one would see a 
straight line.) The first phase may be due to a more 
sensitive form of the enzyme. 
Compound R 95 1, the propiophenone derivative 
of norpethidine, resembles our keto amines in pos- 
sessing a tertiary amine group at the 3-position. 
However, it is an analgesic and, thus, does not seem 
to have significant anti-MA0 activity (Janssen and 
Van Bever, 1977). It is possible that the two bulky 
substituents at the distal end of the piperidine group 
block binding to the active site of MAO. Another 
similar compound, L-51988 (Murphy et at., 1978), is 
also an aminopropiophenone, in which the amine 
group is cyclopropylamine. It is active against both 
types of MAO,  tes ted  in neuroblastoma and 
platelets, particularly toward type A. This differ- 
ence suggests that the long-chain acylamino group 
in our series is a major source of the preference for 
M A 0  type B activity. 
It is possible to calculate the half-life for M A 0  in 
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Monoamine oxidase activity (nmolihlmg protein) 
Brain source Pheneth ylamine Hydroxytryptamine 
Saline-injected control 11.5 18.5 
Drug-injected (after I h) 3.9 3.6 
Mixture with control 8.0 (7.7) 14.1 (11.1) 
Drug-injected (after 2 h) 3.9 4.8 
Mixture with control 7.5 (7.7) 13.2 (11.7) 
Mice were injected with saline or with RV-378 (250 mgikg) and killed after 1 or 2 h.  
The mixed homogenates were assayed by mixing one-half the usual amount of each. 
The predicted activity, shown in parentheses, was calculated by averaging the 
activities found with control and drug-treated homogenates. 
(1962). This method, which was also used by Davis 
and Agranoff (1968) and by Hara and Radin (1979), 
is based on the assumptions that the rate of enzyme 
resynthesis (following its inactivation by an inhib- 
itor) is not affected by the loss of the enzyme 
molecules, that the excess inhibitor is removed 
from the organ fairly quickly, and that the newly 
detected enzyme activity during the recovery pe- 
riod is due to t h e  synthesis of new enzyme 
molecules rather than to the removal of the inhib- 
itory moiety (perhaps by a displacement reaction). 
The calculated half-life for type A MA0 is 13 h, a 
rather rapid turnover rate. Because of the greater 
complexity of MA0 type B (Fig. 3), this calculation 
is inappropriate. 
When pargyline was used in the above manner to 
determine the half-life of brain MAO, longer half- 
lives were obtained, using PEA and 5-HT as sub- 
strates (Maitre et al., 1976). However, when several 
physiological consequences of MA0 inhibition 
were followed as a function of time, rapid recovery 
was observed, from which these authors concluded 
that a second MA0 pool exists, possessing a half- 
life of only 12- 18 h. Goridis and Neff (1971) have 
also observed a slow turnover rate, using the same 
drug and tyramine as substrate. In the case of MA0 
in rat liver mitochondria, Erwin and Deitrich (1971) 
found half-lives closer to our value: 1.8 or 3.5 days. 
Squires and Lassen (1968) have pointed out that 
the time required for half-restoration of brain MA0 
is very much dependent on the nature of the "ir- 
reversible" inhibitor used. This discrepancy could 
be attributed to different rates of enzyme reactiva- 
tion, but it could also be attributed to a variable 
degree of sequestering of each inhibitor in a rela- 
tively protected subcellular site and gradual release 
at a rate sufficient to inactivate some of the newly 
formed MA0 molecules. The latter interpretation 
is supported by the finding that rats given labeled 
pargyline accumulated a significant fraction of the 
labeled material in the liver lysosomes (not a MA0 
site) and that the radioactivity left the lysosomes 
very slowly (Erwin and Deitrich, 1971). Several 
studies have shown that lysosomes tend to take up 
and store basic compounds, into which category 
MA0 inhibitors fall. 
Some of the compounds found to exhibit anti- 
MA0 activity (Table 1) are also excellent inhibitors 
of P-glucosidases (Hyun et al., 1975), which are ap- 
parently sensitive to some of the structural features 
that characterize many MA0 inhibitors. However, 
tests with mouse liver homogenates and the promi- 
nent MA0 inhibitors phenelzine and pargyline at 
0.3 mM did not show any reciprocal inhibition of 
glucosidase activity. 
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